Latest filing published 01 Jun 2023 for TCR2 THERAPEUTICS INC..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Alfonso Quintas Cardama: trading record in brief
Alfonso Quintas Cardama (chief executive) discloses dealings in TCR2 Therapeutics Inc. to SEC (Form 4). In total, 16 filings cover trades dated from 30 August 2019 to 1 June 2023.
No open-market purchase appears, only 8 sales worth €38k. Besides market trades, the filings include 5 share grants and 2 option exercises.
Most recently, on 1 June 2023, the filings show a transaction in TCR2 Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Alfonso Quintas Cardama
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 109,459 sharesCommon StockSEC:0001104659-23-067068:0
- 4,461 shares@ US$1.1326.0% of flowCommon StockSEC:0000899243-22-038387:0
- 3,928 shares@ US$1.28326.3% of flowCommon StockSEC:0000899243-22-038102:0
- 3,686 shares@ US$1.3726.1% of flowCommon StockSEC:0000899243-22-037943:0
- 95,385 sharesCommon StockSEC:0001209191-22-059883:0
- 164 shares@ US$14.2612.1% of flowCommon StockSEC:0001209191-21-069055:0
6 of 6 declarations
